We’re thrilled to announce that MyCural has successfully raised SEK 4 million through a SAFE note this summer — with strong participation from both existing and new investors.
We’re especially proud to welcome prominent investors Krim Talia, Maria Trapp and Linnéa Capital as new investors. Their confidence in our vision and team is a powerful validation of the work we’re doing.
Looking ahead, we’re preparing to open our next larger funding round this autumn. Early commitments are already coming in, and we’re grateful to have the support of UCEA – Family Office Group as we continue scaling.
To our investors, partners, and supporters — thank you! Because of your trust and collaboration, we’re reaching new heights and accelerating toward an exciting future.
MyCural Therapeutics is a drug development company focused on creating novel therapies that target MYC, a key oncogene implicated in over 50% of all high-risk cancers.
